Patent: 10,252,002

« Back to Dashboard

Summary for Patent: 10,252,002

Title:	Continuous glucose monitoring injection device
Abstract:	An electronic insulin delivery device receives glucose data from a glucose monitor and sets a bolus dose amount. The device may take the form of an insulin pen with automatic priming and accurate dosing provided by a motor in connection with an encoder. The device may communicate with and be controlled by a smart phone device. The smart phone device provides a user interface to receive user data including patient weight, insulin to carbohydrate ratio and exercise factor, and to send instructions to the device, including dose amount. The dose amount is determined taking into account glucose level and trend, and other factors. The delivery device may be in continuous communication with the glucose monitor and smart phone to provide for near real-time adjustments in glucose treatment. Glucose data, insulin injection data, and other relevant data may be stored and accessible to interested parties.
Inventor(s):	M. Ishaq Haider, Noel Harvey, Sundeep Kankanala, Frank Martin, Ronald Pettis
Assignee:	Embecta Corp
Application Number:	US15/500,913
Patent Claims:	see list of patent claims

Details for Patent 10,252,002

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2035-07-30

International Patent Family for US Patent 10,252,002

Country	Patent Number	Estimated Expiration
China	107073207
European Patent Office	3174576
European Patent Office	4101483
Spain	2921199
Japan	2017525451
South Korea	102496129
South Korea	20170039273